Terminated PHASE1 INTERVENTIONAL 4-arm NCT01832974

Possible New Therapy for Advanced Cancer

A Phase I/II Trial of IL-13-PE in Patients With Treatment Refractory Malignancies With a Focus on Metastatic and Locally Advanced Adrenocortical Carcinoma

Sponsor: INSYS Therapeutics Inc

Conditions Adrenocortical Carcinoma

Interventions IL-13-PE

Updated 6 times since 2017 Last updated: Apr 24, 2015 Started: Dec 31, 2012 Primary completion: Mar 31, 2014 Completion: Sep 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Business decision by the sponsor during Phase 1.

Other terminated trials from INSYS Therapeutics Inc

More terminations from INSYS Therapeutics Inc

Other Adrenocortical Carcinoma trials with similar outcome

Browse all Adrenocortical Carcinoma trials

A PHASE1 clinical study on Adrenocortical Carcinoma, this trial is terminated or withdrawn. The trial is conducted by INSYS Therapeutics Inc and has accumulated 6 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

INSYS Therapeutics Inc
National Institutes of Health (NIH)

Data source: INSYS Therapeutics Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States